Clinical Trial Update: DORADO - Fixed Doses of Darusentan as Compared to Placebo in Resistant Hypertension [Phase 3]

View source ↗

Summary

Phase 3 trial DORADO evaluating fixed doses of darusentan vs placebo in resistant hypertension has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hypertension

Drugs mentioned

• Darusentan (darusentan)

Snippet

Sponsor: Gilead Sciences | Conditions: Hypertension | Phase 3 | Status: COMPLETED